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Background: Ventilator-associated pneumonia (VAP) remains the leading cause of death in
patients with intensive care unit (ICU) acquired infections associated with an attributable
mortality around 30%. Increasing antimicrobial resistance in patients with VAP challenges
intensivists to search for alternative therapeutic options. There is scarcity of data in the
literature concerning the administration of aerosolized colistin in critically ill patients with
VAP due to multidrug-resistant (MDR) Gram-negative pathogens.
Methods: To assess the safety and effectiveness of aerosolized colistin as an adjunctive to
the intravenous antimicrobial therapy for the treatment of VAP due to MDR Gram-negative
pathogens, we prospectively examined all patients, who received inhaled colistin.
Results: Sixty critically ill patients with a mean APACHE II score 16.7, received aerosolized
colistin for the treatment of VAP due to MDR pathogens [Acinetobacter baumannii (37/60
cases), Pseudomonas aeruginosa (12/60 cases) and Klebsiella pneumoniae strains (11/60
cases)]. Half of the isolated pathogens were susceptible only to colistin. Mean (7SD) daily
dosage of aerosolized colistin was 2.2 (70.7) million international units (IU). All patients
received 2946 inhalations of colistin and the mean duration of administration was 16.4
days. Fifty-seven patients received concomitant intravenous treatment with colistin or
other antimicrobial agents. Bacteriological and clinical response of VAP was observed inElsevier Ltd. All rights reserved.
a; D.F., S.V., C.V., S.R., and Z.M., collected the data; all authors contributed in the writing and
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A. Michalopoulos et al.40850/60 (83.3%) patients. No adverse effects related to inhaled colistin were recorded. All
cause hospital mortality was 25% while mortality attributable to VAP was 16.7%.
Conclusions: Aerosolized colistin may be considered as adjunctive to intravenous
treatment in patients with VAP due to MDR Gram-negative bacteria susceptible to colistin
in critically ill patients. Although colistin is safe and effective, the best route of
administration remains unclear. In addition, controlled comparative studies are needed to
establish its effectiveness and safety.
& 2007 Elsevier Ltd. All rights reserved.Introduction
Ventilator-associated pneumonia (VAP) remains the most
common infectious complication in the intensive care unit
(ICU) setting. Its prevalence varies from 6 to 52 cases per
100 patients depending on the population studied, the type
of ICU, and the diagnostic criteria used.1 ICU patients who
develop VAP are often at greater risk for infection with a
wide spectrum of multidrug-resistant (MDR) Gram-negative
bacterial pathogens, such as Pseudomonas aeruginosa,
extended-spectrum b-lactamase-producing Klebsiella pneu-
moniae strains, and Acinetobacter baumannii. During the
last decade, antimicrobial resistance in Gram-negative
bacteria in ICU patients has been an increasing problem all
over the world. Multidrug resistance among these pathogens
is especially worrisome, as the possible antimicrobial
options are limited.
Recently, there is interest in using polymyxins and
especially colistin (colistimethate sodium) for the treatment
of infections caused by MDR Gram-negative micro-organ-
isms.2,3 VAP due to MDR Gram-negative bacteria is one of the
most serious complications that occur in mechanically
ventilated patients in the ICU setting. It is associated with
increased mortality (up to 65%), morbidity, and hospital
costs.2 Aerosolized colistin has been used mainly in patients
with cystic fibrosis.4 There are few reports, including our
limited initial published experience, indicating that aero-
solized colistin may be a beneficial and safe additional
therapeutic intervention for the management of VAP.5,6
However, the number of patients included was very small. In
this study, we present data from our recent experience with
aerosolized colistin for the treatment of VAP due to MDR
Gram-negative bacteria in 60 critically ill ICU patients.Methods
Design of the study-patient population
We prospectively enrolled to this study all patients who
received nebulized colistimethate sodium (Colomycin, For-
est Laboratoriess, Kent, UK or Colistin, Normas, Athens,
Greece) for the treatment of VAP due to MDR Gram-negative
bacteria from 15/September/2005 to 15/June/2006 in the
38-bed general ICU at ‘‘Henry Dunant’’ Hospital, a 450-bed
tertiary care center in Athens, Greece. Colistin therapy was
initiated in all patients when VAP was documented and the
responsible Gram-negative pathogen was MDR but sensitive
to this antimicrobial agent. The daily dosage of aerosolized
colistin was 3 million international units (IU) divided into 3doses, while the daily dosage of intravenous colistin was 9
million IU divided into 3 doses in patients with normal renal
function. In the elderly patients (age above 80 years), in
patients with body weight less than 50 kg, and in those with
acute or chronic renal failure (serum creatinine above
2mg/dl) the daily dosage of aerosolized colistin was 1.5 million
IU divided into 3 doses. Colistimethate sodium (also called
colistin sulfamethate, colistin methanesulfonate, or colistin
sulfonyl methate) was used in all patients because it is
better tolerated and it is associated with less bronchocon-
striction compared with colistin sulfate.5,7,8 One milligram
of the colistimethate formulations used is approximately
equal to 12,500 IU of colistin. Colistimethate was prepared
for nebulization by dilution of one million IU of colistin in
4mL of sterile normal saline 0.9%. In patients with
mechanical ventilatory support aerosolized colistin was
delivered by means of the Siemens Servo Ventilator 300,
and in the non-ventilated patients (after discontinuation
of the mechanical ventilation) by the same way the inhaled
b2-agonists are given. During aerosolized treatment all
patients with VAP were closely monitored for possible respi-
ratory adverse reactions, such as chest tightness, broncho-
constriction, cough or apnea. Patients’ lung mechanics were
closely monitored during colistin nebulization. All the
procedures used were in accordance with the recommenda-
tions found in the Helsinki Declaration of 1975. The study
was approved by the Institutional Review Board (IRB) of the
hospital. Patient consent was granted.Data collection-entry
Data for several variables including demographics, cause of
ICU admission, APACHE II score on ICU admission, the
responsible pathogens as well as the results of laboratory
and imaging tests including chest X-rays, and/or computed
tomography scans of thorax were recorded in all patients
receiving aerosolized colistin for VAP. Renal function tests
(serum creatinine and urea), liver function tests (serum
alanine aminotransferase, aspartate aminotransferase, al-
kaline phosphatase, g-gloutamyl transpeptidase, and bilir-
ubin), creatine phosphokinase (CPK), and arterial blood
gases taken every hour during the course of aerosolized
colistin treatment (before and after) were also recorded.
The dosage of aerosolized colistin, the duration of this
treatment and any adverse-effect related to this adminis-
tration as well as data regarding the bacteriological and
clinical response of VAP, the duration of mechanical
ventilation, the ICU length of stay and patients’ outcome
were also recorded in all patients.
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Definition of VAP
Pneumonia was considered to be ventilator associated (VAP)
when its onset occurred 48 h after the initiation of
mechanical ventilation and was judged not to have been
incubating before the initiation of mechanical ventilation.
Diagnosis of VAP required the presence of fever (T438.5 1C)
or hypothermia (To36 1C), leukocytosis (WBC412,000/mm3)
or leukopenia (WBCo4000/mm3) and new or progressive
infiltrates on chest radiograph. The diagnosis of VAP had to
be confirmed by positive cultures of bronchial secretions or
bronchoalveolar lavage (BAL) with isolation of MDR Gram-
negative bacterium. The diagnostic threshold of broncho-
scopic BAL for the identification of the VAP responsible
bacteria was 104 cfu/mL. Bacteriologic sampling was per-
formed in all patients on the day VAP was suspected (day 0),
before instituting new antimicrobials.
Definition of multidrug resistance
Gram-negative bacteria were defined as MDR if there was
resistance to all or most of the 6 antipseudomonal classes of
antimicrobial agents, i.e. antipseudomonal penicillins,
cephalosporins, carbapenems, monobactams, quinolones,
and aminoglycosides) for P. aeruginosa and K. pneumoniae,
and in addition, resistance to sulbactam and tetracycline for
A. baumannii (no in vitro susceptibility testing for tigecy-
cline was performed). For this study, intermediate suscept-
ibility was considered as resistance.
Definition of outcome
The definition of positive outcome (cure or improvement) of
pneumonia was based on clinical (defeversense, resolution
or partial resolution of presenting symptoms and signs of
pneumonia, decrease of suctioning requirements), radiolo-
gical (decrease or disappearance of the presenting findings
on the chest X-ray) and laboratory findings (improvement of
arterial blood gases, and normalization of white blood cell
count, C-reactive protein, and procalcitonin).
Outcome parameters
The primary endpoint of the study was all-cause in-hospital
mortality. Secondary endpoints included the clinical and
bacteriological outcome of the infection (VAP) and the
occurrence of adverse events during colistin treatment, and
were defined as follows: clinical cure was defined as
resolution of presenting symptoms and signs of infection
by the end of colistin treatment; clinical improvement was
defined as partial resolution of presenting symptoms and
signs of infection; clinical failure (unresponsiveness) was
defined as persistence or worsening of presenting symptoms
and/or signs of infection during colistin administration;
undetermined was recorded when clinical assessment was
not possible; recurrence of infection was defined as the
occurrence of a new episode of infection at least 72 h after
clinical resolution of a preceding episode. The evaluation ofclinical response was made on the basis of the resolution of
clinical signs and symptoms, including fever, leukocytosis
and improvement of chest X-rays (for pneumonia). Bacter-
iological outcome of the infection was defined as follows:
eradication of the pathogen was defined as no growth of the
pathogen in the final culture of specimens during the whole
hospitalization; persistence of the pathogen was defined
as persistent growth of the responsible pathogen regardless
of the clinical outcome of the infection; recurrence
(re-growth) of the pathogen was defined as re-isolation
of the same pathogen regardless of the clinical outcome
of the infection; colonization was defined as persistence or
re-growth of the pathogen without symptoms and signs of
infection; undetermined was recorded when microbiological
assessment was not possible. Assessment of effectiveness
was made at the end of colistin treatment.
Safety parameters
All adverse effects related to inhaled colistin such as
bronchoconstriction, cough, apnea, or chest tightness, and
arterial hypoxemia were recorded in every patient. In
addition, safety was assessed on the basis of laboratory test
results for renal function (changes from baseline in serum
urea and creatinine levels) during colistin administration.
Normal renal function was defined as a serum creatinine
level of p1.2mg/dL. Acute renal failure was defined as a
rise of 2mg/dL in the serum creatinine level of patients with
previously normal renal function. In patients with a history
of renal insufficiency, acute or chronic renal failure was
defined as at least a doubling of the baseline serum
creatinine level (defined as the creatinine level at the
initiation of colistin treatment). Organ function was
evaluated daily according to the Sequential Organ Failure
Assessment (SOFA) score. For each of the 6 organ systems
included in the SOFA score (respiratory, cardiovascular,
neurological, renal, hematological and hepatic), organ
failure was defined as a score of X3.9 Prognostic factors
possibly associated with adverse outcome (death) were
examined during the evolution of the infection until the end
of colistin treatment. We also recorded any consequent
nosocomial-acquired infection, the development of resis-
tance against colistin, as well as the selection of fungi
following administration of colistin.
Results
Sixty adult critically ill patients received aerosolized colistin
as adjunctive treatment for the management of VAP due to
MDR Gram-negative bacteria. The patients were 40 males
and 20 females and had a mean [7standard deviation
(7SD)] age 59.4 (718.3) years. Patients had a mean (7SD)
Acute Physiological and Chronic Health Evaluation II
(APACHE II) score on the day of ICU admission of 16.7
(75.1). The episodes of VAP were developed between the
3rd and 38th day of mechanical ventilation (mean 11th day).
Fifty-seven out of 60 patients received concomitant in-
travenous treatment with colistin and other antimicrobial
agents (usually meropenem). The selection of the second
antibiotic basically was based on the susceptibility test and
MICs. The remaining 3 patients received inhaled colistin plus
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biotics administered intravenously in this group of patients
with VAP due to multi-resistant Gram-negative bacteria are
presented in Table 2. The mean first day of aerosolized
colistin administration was the 11th day of mechanical
ventilation.
The responsible pathogens of VAP were A. baumannii
(37/60 cases), P. aeruginosa (12/60 cases) and K. pneumoniae
strains (11/60 cases). Tables 1 and 2 describe the demo-
graphic and clinical features of patients, the responsible
pathogens, as well as the outcome of the infection and of
the patients. Half of the isolated pathogens were suscep-
tible only to colistin. Mean (7SD) daily dosage of aero-
solized colistin was 2.2 (70.7) million IU, ranging from 1.5
to 3 million IU (divided into 3 doses). Totally, all patients
received 2946 inhalations of colistin and the mean duration
of administration was 16.4 (710.9) days (ranged from 5 to
49 days). Bacteriological and clinical response of VAP
associated with improvement of chest X-ray and arterial
blood gases, and normalization of white blood cell count,
C-reactive protein, and procalcitonin was observed in 50 out
of 60 patients (83.3%). Clinical response of VAP due to MDR
Gram-negative pathogen sensitive only to colistin is shown in
Table 3.
No adverse effects related to inhaled colistin (broncho-
constriction, cough, apnea, or chest tightness) were
recorded. Arterial blood gases and lung mechanics did not
alter during colistin inhalation in all patients. However, 12
patients with history of chronic obstructive pulmonary
disease (COPD) received concurrent treatment with inhaled
b2-agonist. Mean (7SD) total mechanical ventilatory sup-
port was 27.4 (718.5) days. Mean (7SD) ICU stay was 32.5
(719.7) days. Colistin-associated side effects, such as
paresthesias, vertigo, or muscle weakness were not ob-
served. No other complication possibly related to colistinTable 1 Demographics, clinical data, responsible
pathogens, bacteriological and clinical outcome of VAP
and outcome of critically ill patients who received
aerosolized colistin.
Variables Value
No. of studied patients 60
Age (years) 59.4 (718.3)
Gender (males) 40/60 (66.7%)
Apache II on ICU admission 16.7 (75.1)
Duration of mechanical ventilation
(days)
27.4 (718.5)





Microbiological eradication 50/60 (83.3%)
Cure or improvement of VAP 50/60 (83.3%)
Acinetobacter baumannii 31/37 (83.8%)
Pseudomonas aeruginosa 10/12 (83.3%)
Klebsiella pneumoniae 9/11 (81.8%)
Discharge from hospital 45/60 (75%)administration was recorded. In the subgroup of patients
(n ¼ 57) who received a combination of antibiotics including
colistin administered both intravenously and inhaled and
had a normal renal function prior to ICU admission, 9 (15.7%)
patients developed acute renal failure. However, the
majority of these patients developed renal failure asso-
ciated with multiple organ failure.
All cause hospital mortality was 15/60 (25%). Patients
with VAP due to MDR Gram-negative bacteria associated
with poor prognosis died from septic shock and multiple
organ failure. Out of 50 patients with bacteriological and
clinical response of VAP, 3 patients developed later on during
ICU stay candidemia, one developed a second episode of VAP
due to Stenotrophomonas maltophilia and another one
wound infection and finally died. Attributable mortality in
patients with VAR due to MDR Gram-negative bacteria was
10/60 (16.6%). Patients with good outcome of VAP were
discharged from the ICU and the hospital.Discussion
The main finding of this study is that aerosolized colistin may
be an effective and safe adjunctive treatment of VAP due to
MDR Gram-negative bacteria in critically ill adult patients in
the ICU setting. This finding has clinical interest because VAP
remains a serious and common infectious complication in
patients with prolonged ventilatory support and is clearly
associated with increased morbidity, mortality and total
hospital costs. However, since randomized-controlled trials
are missing, the best route of colistin’s administration
remains unclear.
Colistin (or polymyxin E) is an old antibiotic discovered
from different species of Bacillus polymyxa in the decade of
1940s and was extensively used parenterally for more two
decades. Subsequently, polymyxins were gradually with-
drawn from clinical practice for many years owing to reports
of nephrotoxicity and neurotoxicity.10,11 Two different forms
of colistin are available for clinical use; colistin sulfate
orally for bowel decontamination and topically as a powder
for the treatment of bacterial skin infections, and colisti-
methate sodium for parenteral and aerosol therapy. Colis-
timethate sodium is a basically a pro-drug of colistin.12,13
Colistin has rapid concentration-dependent bactericidal
activity against Gram-negative pathogens and exhibits
considerable post-antibiotic effect. It has excellent anti-
microbial activity against most of the Gram-negative
microorganisms, including P. aeruginosa, A. baumannii,
and K. pneumoniae. The re-introduction of polymyxins in
clinical practice during the last years was the result of the
increased resistance rates among Gram-negative bacteria,
especially in the ICU setting, and the absence of new and
effective alternative therapeutic options.14 There have
been several recent studies showing that intravenous
colistin is an effective and safe antimicrobial agent in the
treatment of most types of Gram-negative infections,
including hospital-acquired pneumonia and VAP due to MDR
Gram-negative pathogens.3,15
There are many reports in the literature concerning the
effectiveness of aerosolized colistin in preventing relapses
of lung infections,16 the eradication of P. aeruginosa from
the respiratory tract,17 and the treatment of respiratory
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bacteria who received aerosolized colistin.




Meropenem+colistin 31 25 (80.6) 25 (80.6) 9 (29) 6 (19.3)
Piperacillin/tazo+colistin 11 9 (81.8) 9 (81.8) 3 (27.3) 2 (18.2)
Ampicillin/
sulbactam+colistin
6 5 (83.3) 5 (83.3) 2 (33.3) 2 (33.3)
Imipenem+colistin 4 3 (75) 3 (75) 1 (25) 0
Gentamicin+colistin 3 3 (100) 3 (100) 0 (0) 0
Meropenem 3 3 (100) 3 (100) 0 (0) 0
Third-generation
cephalosporin+colistin
1 1 (100) 1 (100) 0 (0) 0
Cefepime+colistin 1 1 (100) 1 (100) 0 (0) 0
aIf the entry is n (p), n is the number and p is the percentage.
Table 3 Patients with VAP due to multidrug-resistant Gram-negative pathogens sensitive only to colistin (n ¼ 30).
Pathogen of VAP Patientsa Clinical response of VAPa In-hospital deatha
Acinetobacter baumannii 19/37 (51.3) 14/19 (73.7) 5/19 (26.3)
Pseudomonas aeruginosa 6/12 (50.0) 4/6 (66.7) 2/6 (33.3)
Klebsiella pneumoniae 5/11 (45.4) 3/5 (60.0) 2/5 (40.0)
aIf the entry is n (p), n is the number and p is the percentage.
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with cystic fibrosis. In addition, aerosolized colistin has been
used successfully for prophylaxis and treatment of pneumo-
nia caused by P. aeruginosa in patients with human
immunodeficiency virus (HIV) infection.19,20
In patients without history of cystic fibrosis or HIV
infection, aerosolized colistin was used recently as supple-
mentary therapy to the conventional intravenous antibiotic
treatment for the treatment of nosocomial or ICU-acquired
pneumonia caused by MDR Gram-negative microorganisms
with good results.5,6
The dosage of aerosolized colistin recommended in the UK
is 500,000 IU every 12 h for patients with body weight
p40 kg and 1 million IU every 12 h for patients with body
weight 440 kg. For recurrent pulmonary infections, the
dosage can be increased to 2 million IU every 8 h. Dosage
adjustments are recommended for patients with mild-to-
moderate renal dysfunction.21
As far as the possible adverse effects (bronchospasm,
chest tightness, and apnea due to neuromuscular blockade)
of aerosolized colistimethate, no complication from the
respiratory system occurred in our patients. However, it
should be noted that 12 out of 60 studied patients who had
history of COPD received concurrent treatment with inhaled
b2-agonist. This finding is in agreement with the report of
Hamer22 that none of the patients described in his report
experienced any adverse effects from the respiratory system
related to aerosolized colistin. Similarly, the study by Kwa et
al.6 reported that only 1 out of 21 patients receiving
aerosolized colistin suffered from bronchospasm likely
associated with this treatment. In addition, a recent studyshowing that inhaled colistin can cause bronchospasm
particularly in patients with history of bronchial asthma
(preexisting bronchial hyperreactivity).23 However, treat-
ment with inhaled b2-agonists before the initiation of
aerosolized colistin could prevent the development of such
adverse effects from the respiratory system. It should be
emphasized that aerosolized colistin should be administered
immediately after its preparation because of the molecule
instability.
Our study is not without limitations. It is not a
comparative study; specifically we did not have a control
group of patients with VAP due to MDR Gram-negative
pathogens receiving treatment with only intravenous anti-
microbial agents. The open-label, non-controlled design of
this study has the potential to limit the possibility to draw
definite conclusions about efficacy of this treatment
approach. However, the observed clinical outcomes (survival
and clinical response of infection) are better compared with
historical controls with comparable severity of disease as it
is evident from the distribution of the APACHE II score of our
patients.2 Although firm conclusions cannot be made, the
good outcome of our critically ill patients who received
aerosolized colistin as an adjunctive treatment, despite the
severity of their infection and their high APACHE II scores, is
promising.Conclusion
The data from this case series including a relatively large
number of patients suggest that aerosolized colistin may be
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patients with VAP due to MDR Gram-negative bacteria.
Despite this encouraging finding, the best route of colistin’s
administration remains unclear. Subsequently, randomized
controlled trials studying the possible benefits and risks
related to the use of aerosolized colistin in addition to the
intravenous antimicrobial treatment, in patients with VAP
due to MDR Gram-negative bacteria are urgently needed.
Meanwhile, strict use of colistin is required to prevent the
rapid development of emergence and dissemination of
pandrug-resistant Gram-negative bacteria (development of
resistance against colistin), and selection of fungi.
Key messages1. Aerosolized colistin may be considered as adjunctive to
intravenous treatment in patients with VAP due to MDR
Gram-negative bacteria susceptible to colistin.2. Although aerosolized colistin appears to be safe, its exact
role in the treatment of VAP due to MDR Gram-negative
bacteria in critically ill patients remains unclear due to
the scarcity of comparative studies examining different
routes of administration of colistin.3. The co-administration of aerosolized colistin was asso-
ciated with good results in 60 adult patients with VAP.4. Randomized controlled trials examining the possible
benefits and risks related to the use of aerosolized
colistin in addition to the intravenous antimicrobial
treatment, in patients with VAP due to MDR Gram-
negative bacteria are urgently needed.5. Strict use of colistin is required to prevent the rapid
development of emergence and dissemination of pan-
drug-resistant Gram-negative bacteria (development of
resistance against colistin), and selection of fungi.
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